Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study

Recruiting now · Not applicable

Conditions studied: Sensory Neuronopathy

In brief

Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4. The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations. As a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.

Key facts

Study ID

NCT07651540

Run by

Centre Hospitalier Universitaire de Saint Etienne

People needed

70

Starts

2026-07-06

Expected to finish

2028-06-25

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient affiliated with or beneficiary of a social security system
• Patient having received appropriate study information
• Adult patient ≥18 years old, male or female
• Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
• SN with one of the following etiologies:
• Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome

You may not qualify if…

• Patient unable to understand or read French
• Patient refusal to participate
• Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including:
• Diabetes mellitus
• Significant alcohol consumption
• Severe chronic kidney disease (GFR <30 ml/min)
• Vitamin B12 and/or vitamin E deficiency
• Vitamin B6 excess
• Chemotherapy other than platinum salts
• HIV infection

Where it is running

• Chu de Saint-Etienne — Saint-Etienne, France (enrolling)
• Chu de Clermont Ferrand — Clermont-Ferrand, France
• Chu de Grenoble — Grenoble, France
• Chu de Lille — Lille, France
• Chu de Limoges — Limoges, France
• Hospices Civils de Lyon — Lyon, France
• Hopitaux Universitaire de Marseille — Marseille, France
• Chu de Nancy — Nancy, France
• Chu de Nantes — Nantes, France
• Chu de Nice — Nice, France
• Hopital, Bicetre — Paris, France
• CHU St Etienne — Saint-Etienne, France
• Chu de La Reunion — Saint-Pierre, France
• Hopitaux Universitaire de Strasbourg — Strasbourg, France
• Chu de Toulouse — Toulouse, France
• Hopitaux Universitaire de Geneve — Geneva, Switzerland
• Chuv Centre Hospitalier Vaudois — Lausanne, Switzerland
• Chu D Angers — Angers, France
• Hopital de Sion — Sion, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.